Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gamma-aminobutyric acid receptor benzodiazepine binding site refers specifically to an allosteric modulatory pocket formed at certain interfaces within heteropentameric GABAA receptors. It underlies both therapeutic actions and side effects associated with drugs like diazepam through potentiation—not direct activation—of inhibitory neurotransmission in CNS neurons. The classical binding site is located at the interface between an α subunit (specifically α1, α2, α3, or α5) and a γ2 subunit in receptors that also contain β subunits. Benzodiazepines act as positive allosteric modulators, enhancing the effect of endogenous GABA by increasing chloride ion influx through the channel when activated by GABA. This leads to hyperpolarization of neurons and decreased neuronal excitability.
Positive allosteric modulation of GABAA receptor activity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric Acid (GABA) Receptor Benzodiazepine Binding Site (BZR).